Yumeng Mao Selected Research

Yumeng Mao Research Topics

Disease

16	Neoplasms (Cancer) 01/2021 - 05/2010
4	Melanoma (Melanoma, Malignant) 01/2021 - 07/2013
3	Breast Neoplasms (Breast Cancer) 11/2013 - 03/2012
2	Ovarian Neoplasms (Ovarian Cancer) 08/2020 - 01/2020
2	Neuroblastoma 01/2016 - 01/2016
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Adenocarcinoma of Lung 01/2021
1	Squamous Cell Carcinoma of Head and Neck 01/2021
1	Tics (Tic) 08/2020
1	Ascites 08/2020
1	Bites and Stings (Sting) 01/2020
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2020
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2016
1	Ataxia Telangiectasia (Louis Bar Syndrome) 03/2012

Drug/Important Bio-Agent (IBA)

3	Dinoprostone (PGE2)FDA Link 01/2021 - 07/2013
3	Blocking AntibodiesIBA 08/2020 - 01/2016
2	Interleukin-15 (Interleukin 15)IBA 01/2021 - 01/2016
2	Immune Checkpoint InhibitorsIBA 08/2020 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2010
2	4- (2- (2- hydroxycyclohexylamino)benzothiazol- 6- yloxy)pyridine- 2- carboxylic acid methylamideIBA 01/2016 - 01/2016
2	Macrophage Colony-Stimulating FactorIBA 01/2016 - 01/2016
2	HLA-DR Antigens (HLA-DR)IBA 08/2014 - 07/2013
1	PlatinumIBA 01/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021
1	Prostaglandin-E SynthasesIBA 01/2021
1	CytokinesIBA 01/2021
1	Interleukin-2 (IL2)IBA 01/2021
1	Cisplatin (Platino)FDA LinkGeneric 01/2021
1	NivolumabIBA 08/2020
1	MethyltransferasesIBA 08/2020
1	A-Form DNA (A-DNA)IBA 08/2020
1	Toll-Like Receptor AgonistsIBA 01/2020
1	Pharmaceutical PreparationsIBA 01/2020
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020
1	Pattern Recognition ReceptorsIBA 01/2020
1	NLR ProteinsIBA 01/2020
1	Therapeutic UsesIBA 01/2016
1	ChemokinesIBA 01/2016
1	VaccinesIBA 06/2015
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 08/2014
1	Biomarkers (Surrogate Marker)IBA 03/2014
1	Amino Acids FDA Link 11/2013
1	Phenobarbital (Luminal)FDA Link 11/2013
1	Immune Checkpoint ProteinsIBA 09/2013
1	IpilimumabIBA 09/2013
1	Superoxides (Superoxide)IBA 07/2013
1	ArginaseIBA 11/2012
1	EnzymesIBA 11/2012
1	ErbB Receptors (EGF Receptor)IBA 10/2012
1	Caffeine (No Doz)FDA LinkGeneric 03/2012
1	LigandsIBA 03/2012
1	Protein Kinases (Protein Kinase)IBA 03/2012
1	MHC class I-related chain AIBA 03/2012
1	Phosphotransferases (Kinase)IBA 03/2012
1	tyrosine receptor (receptor, tyrosine)IBA 03/2012
1	micaIBA 03/2012
1	NeuregulinsIBA 03/2012
1	AntibodiesIBA 05/2010

Therapy/Procedure

7	Immunotherapy 01/2021 - 05/2010
4	Therapeutics 08/2020 - 03/2014
1	Drug Therapy (Chemotherapy) 08/2020
1	Combined Modality Therapy 01/2016